Inflammatory Myositis Market
In 2023, the Inflammatory myositis market in the US stood out prominently among the seven major markets (7MM), reaching an impressive USD 301 million. This significant figure not only underscores the current robust demand but also highlights the substantial growth potential within this sector. As the understanding and management of inflammatory myositis evolve, the market is poised for continued expansion, with projections indicating a steady increase in market size through 2034.
The market for therapeutics targeting Inflammatory Myositis is projected to experience robust growth, with an anticipated compound annual growth rate (CAGR) of approximately 11.7% in the 7MM. This dynamic expansion reflects increasing demand for advanced treatment options and underscores the growing investment in addressing this serious condition.
Some of the products that are likely to hit the market during the study period 2020–2034 include PF-06823859, Brepocitinib, and others.
Recent Development:
- In June 2024, Cabaletta Pharmaceuticals unveiled promising initial clinical data from the first patient in the immune-mediated necrotizing myopathy (IMNM) cohort of their groundbreaking Phase I/II RESET-Myositis trial, showcasing three months of follow-up results
- These compelling findings were highlighted at a prestigious satellite symposium during the EULAR 2024 Congress, underscoring the potential of Cabaletta’s innovative approach
- Patient enrollment for the RESET-Myositis trial is actively progressing, with further detailed clinical data anticipated in the latter half of 2024
- This ongoing research positions Cabaletta at the forefront of developing transformative therapies for IMNM
Inflammatory Myositis Treatment Market
The term myositis refers to a condition where there is inflammation of muscle. In practice, myositis tends to be associated with the inflammatory myopathies: polymyositis, dermatomyositis, myositis associated with cancer, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). Myopathy, by contrast, refers to any abnormal condition or disease of muscle and, by definition, includes myositis.
Myositis is a rare condition that can affect multiple organs apart from muscles and often leads to severe impairment of the quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases where the body’s immune system mistakenly attacks its muscles. The most common inflammatory myopathies are dermatomyositis and polymyositis.
Inflammatory Myositis Diagnosis
Diagnosing myopathies involves a laboratory evaluation, imaging studies, multidisciplinary consultations, histologic examination, and potentially genetic studies. Key diagnostic steps include:
- Thorough history and physical examination
- Routine laboratory tests including complete blood count, complete metabolic panel, muscle enzymes, and thyroid-stimulating hormone
- Autoimmune serologies and imaging studies
- Neurologic evaluation, EMG, nerve conduction velocities, and muscle biopsy
Inflammatory Myositis Treatment
The treatment landscape for inflammatory myositis involves a combination of medications and supportive therapies. The specific treatment approach may vary depending on the individual’s symptoms, disease severity, and response to previous treatments. Common treatment options include:
- Corticosteroids: High-dose corticosteroids, such as prednisone, are often the first-line treatment. They help reduce inflammation and suppress the immune response, with dosage gradually reduced to find the lowest effective dose
- Immunosuppressants: Medications such as methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine may be added if corticosteroids are insufficient, working by suppressing the immune system and reducing inflammation
- Biologic agents: In more severe or refractory cases, biologics such as rituximab, tocilizumab, or abatacept may be considered to target specific immune cells involved in the disease process
- Intravenous immunoglobulin (IVIG): A treatment option for some individuals with dermatomyositis or polymyositis who do not respond adequately to other therapies
It is important to note that inclusion body myositis (IBM) treatment is particularly challenging, as it is generally less responsive to immunosuppressive therapies. Currently, no specific treatment can stop or reverse IBM progression; however, supportive therapies and physical therapy can help improve quality of life.
A high unmet need prevails in current therapies for treating inflammatory myositis. To cater to these needs, many molecules are in the pipeline across the 7MM. Reflecting the broader Inflammatory myositis market trends, key pipeline candidates anticipated between 2020–2034 include PF-06823859, Brepocitinib, and others.
Inflammatory Myositis Epidemiology
As the market is derived using a patient-based model, the epidemiology analysis covers historical and forecasted data segmented across the 7MM – including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan – from 2020 to 2034.
Key epidemiological highlights include:
- There were 188 thousand diagnosed prevalent cases of inflammatory myositis estimated in the 7MM in 2023, of which 92 thousand were from the US alone – cases are anticipated to increase during the forecasted period
- Type-specific diagnosed prevalent cases in the 7MM in 2023 were categorized into PM (76 thousand), DM (84 thousand), and IBM (27 thousand), all of which are expected to rise by 2034
- Age-specific cases in the EU4 and the UK in 2023 were distributed as: 0–17 years (3 thousand), 18–44 years (12 thousand), 45–64 years (25 thousand), and 65 years and above (29 thousand)
- Gender-specific diagnosed prevalent cases in Japan in 2023 included 10 thousand males and 15 thousand females
This epidemiological scope forms a critical foundation for Inflammatory myositis market research, enabling stakeholders to understand disease burden and project future therapeutic demand with precision.
Inflammatory Myositis Emerging Drugs
- Dazukibart (PF-06823859) – Pfizer
Dazukibart (PF-06823859) is an advanced investigational monoclonal antibody developed by Pfizer, specifically engineered to target and modulate key immune system components involved in autoimmune diseases. It is currently under evaluation for its efficacy in treating patients with inflammatory myositis, where elevated levels of pathogenic immunoglobulin G (IgG) autoantibodies are commonly observed.
- Dazukibart has been granted Orphan Drug Designation (ODD) by both the US FDA and EMA
- It has received Fast Track Designation (FTD) by the FDA for the treatment of Dermatomyositis and Polymyositis
- The EMA has awarded PRIME status to Dazukibart, further validating its potential clinical importance
PF-06823859 represents a pioneering step in addressing the unmet medical needs of inflammatory myositis patients, offering new hope where traditional therapies have proven inadequate. These pipeline advances significantly shape Inflammatory myositis market insight, as they signal a maturing therapeutic landscape with several promising candidates nearing commercialization.
Brepocitinib is another key pipeline asset anticipated to contribute meaningfully to the evolving treatment landscape, reflecting ongoing momentum in JAK inhibitor research for inflammatory conditions.
Leading Inflammatory Myositis Companies
The competitive landscape continues to expand as major pharmaceutical and biopharmaceutical players invest in novel therapeutic approaches. The leading companies developing therapies include:
- CSL Behring
- Immunoforge Co. Ltd.
- Argenx
- Janssen
- Abcuro, Inc.
- Horizon Therapeutics
- Merck KGaA
- Galapagos NV
- Priovant Therapeutics
- Roivant
- Alexion Pharmaceuticals
- Pfizer
- Kezar Life Sciences, and others
Conclusion
The Inflammatory myositis market stands at a pivotal inflection point, shaped by a confluence of rising patient awareness, advancing diagnostics, and a richly populated pipeline. With a projected CAGR of approximately 11.7% across the 7MM through 2034, the sector presents compelling opportunities for biopharmaceutical innovators, investors, and healthcare stakeholders. From the regulatory milestones achieved by Dazukibart to Cabaletta’s groundbreaking RESET-Myositis trial data, the momentum is unmistakably building toward a transformed treatment paradigm – one that offers real hope for patients long underserved by existing therapies.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
